-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Chemomab Therapeutics Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2024.
- Chemomab Therapeutics Ltd. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$3.63M, a 54.4% increase year-over-year.
- Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$24.2M, a 12.4% increase from 2022.
- Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$27.6M, a 122% decline from 2021.
- Chemomab Therapeutics Ltd. annual Net Income (Loss) Attributable to Parent for 2021 was -$12.5M, a 110% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)